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Abstract: Objective: Cost-of-illness studies in Adult Congenital Heart Disease
(ACHD) have mainly been limited to hospitalizations. This is the first paper to
provide a comprehensive overview from a societal perspective including inpatient
and outpatient medical costs, and absenteeism- and unemployment-related socie-
tal costs. Methods: A retrospective longitudinal (2006–2015) database analysis
was performed in Belgium combining administrative and clinical databases
(n = 10,572). Trends in resource use and costs per patient year were standardized
to assess the impact of changes in the patient population composition. Generalized
Linear Mixed Models assessed the impact of age, sex, lesion complexity, and
time. Costs were converted to 2018 values. Results: Medical costs per patient
year increased from V3490 to V4536 with a milder increase in patients with
severe lesions. Although unemployment-related costs decreased, total societal
costs increased due to more long-term (≥1 yr) invalidity. An increase in long-term
invalidity was particularly found in patients ≥30 yrs and in patients with mild or
moderate lesions. Resource use (e.g., dental care, nursing care, physiotherapy,
emergency department) increased substantially in all patient groups over time. The
annual percentage of patients with severe lesions receiving any cardiac and spe-
cialized cardiac follow-up increased with respectively 11 and 13 percent points to
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81% and 52%, with a simultaneous decrease in hospitalization rate. Conclusion:
Medical cost increases in ACHD are most pronounced in patients with mild and
moderate lesions, relatable to their higher age. Economic data are necessary to
allocate resources efficiently to ensure sustainable, qualitative care in an ageing
patient population with strong increases in medical and long-term invalidity-
related costs.
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1 Introduction
Medical progress, in combination with stronger organizational structures and improvements in general
healthcare have seen a rapidly expanding adult patient population with congenital heart disease (CHD) [1,2].
Substantial yearly increases in absolute hospitalization numbers have been reported worldwide [3], and have
imposed a growing burden on financial resources [4].
Costs have mainly been estimated based on hospitalizations rather than on outpatient care, despite the
fact that the latter is a key element in care for adult congenital heart disease (ACHD) as lifelong follow-up is
recommended to detect deterioration in a timely manner [5]. According to a recent systematic review, the
number of outpatient cardiology visits increased by 8.2%–11.4% per year in the last few decades [3]. To
the best of our knowledge, no cost data have been published on outpatient cardiac care, although such
data could be beneficial in determining the most appropriate care level [5]. Moreover, literature on other
outpatient healthcare utilization (HCU) remains scarce [6,7]. Previous research on hospitalization and
outpatient care showed the importance of stratifying results by age, sex, and lesion complexity [3].
Furthermore, whether absenteeism and unemployment rates are higher in the ACHD population than in
the general population appeared to vary by country [8]. Societal cost estimates are scarce [9].
A Belgian study was hence carried out (i) to describe long-term (2006–2015) inpatient and outpatient
HCU, (ii) to calculate the associated medical costs for the health insurance and the patient (‘health
expenditures’), as well as absenteeism-related and unemployment-related societal costs, and (iii) to
determine the impact of age, sex, time, and lesion complexity. This study aims to address a knowledge
gap that has already been identified by Task Force 5 at the 32nd Bethesda conference. The call was made
then to study ACHD economics from a broad perspective, including outpatient medical costs and societal




A detailed description of the Belgian Congenital Heart Disease Database combining Administrative and
Clinical data (BELCODAC) has been published elsewhere [11]. Briefly, the BELCODAC holds healthcare
utilization data from ten consecutive years (i.e., 2006–2015), and clinical data from the same time period and
before (e.g., information on early interventions). In particular, ten databases from five organizations were
merged:
• The Intermutualistic Agency (IMA) is the umbrella organization of the seven Belgian sickness funds.
The IMA delivered three population-level databases: (i) The population database (sociodemographic
information), (ii) The pharmanet database (information on medications and their supply), and (iii) The
medical claims database (medical care information).
• Statistics Belgium collects, processes and distributes data about Belgian society, and delivered four
population-level databases: (i) The death certificate database, (ii) The sociodemographic database,
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(iii) The socioeconomic database, and (iv) The tax income statistics of the Belgian Federal Public
Service Finance, also known as the Impôt des personnes Physiques CALculé (IPCAL) database.
• Ghent University Hospital, University Hospitals Leuven and St-Luc University Hospitals each
provided part of the study population and delivered clinical information.
2.2 Study Population
ACHD care is quite well-established in Belgium (11.4 million inhabitants), with four specialized
hospitals designated to provide the full spectrum of CHD care, including congenital cardiac surgery [12],
and established outpatient clinics in affiliated satellite centers. Three out of the four specialized hospitals
took part in this study. Ghent University Hospital and University Hospitals Leuven selected all
CHD patients who attended the specialized clinic at least once in their life. Patients of St-Luc University
Hospital with severe lesions were included to ensure a reasonable sample size, so that cost-of-illness
estimates would be stable for all subgroups [13]. An open cohort study was applied, with the inclusion
of all living patients, and 18 years or older on 1 January during at least one year of the study period
(2006–2015).
2.3 Outcome Measures
Results are reported as the annual percentage of patients requiring a certain type of HCU, and the per
patient year number of visits per HCU type. Outpatient cardiology visits were classified as pediatric,
ACHD, or general cardiology visits. Other HCU were hospitalizations (both cardiac and noncardiac) and
length of stay (LOS), general practitioner (GP) visits, emergency department (ED) visits, outpatient visits
to noncardiac medical specialists, dental care visits, physiotherapy visits and nursing visits (e.g., wound
care in a home situation or outpatient visits).
Medical costs consisted of hospitalization, outpatient, and pharmaceutical costs. Out-of-pocket costs and
reimbursed costs were analyzed separately. The societal costs consisted of unemployment and medical-
related absenteeism costs. The latter was further classified as absenteeism for less than 1 year (in Belgium
called ‘incapacity to work’), and absenteeism for more than 1 year (‘invalidity’). Short-term absenteeism
(i.e., of less than one month for white-collar employees (≈clerical staff) and self-employees, and less than
14 days for blue-collar employees (≈manual workers)) was not included in the available data as this
period is covered by the employer. Societal costs were calculated by multiplying the number of days
unable to work by the average cost of absenteeism in Belgium [14], thus representing the potential
productivity gain with full employment. All costs were inflated to 2018 euro values using the consumer
price index [15].
2.4 Statistical Analysis
The same epidemiological approach as in a recent paper on trends in palliative home care was used [16].
First, trends in HCU were plotted with descriptive, actual rates per year. Second, direct standardization was
used to adjust for changes in the patient cohort composition during the study period. Standardization was
based on age category (i.e., 18–29 y, 30–39 y, and ≥40 y), sex (i.e., men, women), and lesion complexity
(i.e., mild, moderate, and severe) as defined by Task Force 1 at the 32nd Bethesda Conference [17]. The
first year of the study period (i.e., 2006) was used as the base year, and that year’s composition of patient
population characteristics (i.e., eighteen categories based on age category, sex, and lesion complexity)
were kept constant over the entire study period. Then, for each year in the study period, the actual rate of
HCU within each of the eighteen categories was applied to the base year’s patient population distribution
to obtain the standardized HCU rate per year:
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Here Hct stands for HCU (e.g., number of hospitalizations) in a given category c (e.g., 18–29 year old
man with severe lesion) in a given year t (e.g., 2006–2015); Nct is the number of patient years in the given
category c in the given year t; Nc2006 is the number of patient years in the given category c in 2006; N2006 is
the total number of patient years in 2006.
The closer the actual and standardized (std) HCU rates were, the less impact possible changes in
patient population composition had (or the composition was stable), and the more strongly the trends in
HCU were impacted by within-group variation. Conversely, more pronounced differences between the
actual and standardized HCU rates suggested a changing patient population composition in terms of age,
sex, and complexity.
All data showed positively skewed distributions. Generalized linear mixed models with the log-link
function and a negative binomial distribution were used to assess the impact of time, sex, lesion
complexity, and age on count data such as HCU. A gamma distribution was applied if the dependent
variable reflected cost data. Collinearity diagnostics were conducted, and tolerance values of 0.4 or lower
were considered to reflect multicollinearity. p-values of ≤0.05 were considered statistically significant.
The analysis was performed using SAS Enterprise Guide V.7.1 (SAS Institute, Cary, NC, USA).
2.5 Patient and Public Involvement Statement
Not applicable.
3 Results
A complete overview of the results can be found in Appendix.
3.1 Study Population Characteristics
The patient population increased by 36.6% from 7408 in 2006 to 10,122 in 2015. The mortality rate was
low, with less than 1% of patients dying each year (i.e., varying between 20 deaths in 2006 and 68 deaths in
2015). Mortality was significantly higher in patients with severe lesions than in patients with mild lesions
(Odds Ratio (OR) = 1.67) or moderate lesions (OR = 1.39). Mortality was also significantly higher in
patients ≥40 y compared to patients 18–29 yrs (OR = 5.72) and patients 30–39 yrs (OR = 4.32). Sex
distribution was nearly equal. The average age increased over the study period by 1.6 years reaching
38.3 years. Patients with mild lesions represented over half of the patient population throughout the study
period, but the number of patients with moderate and severe lesions increased proportionally (Fig. 1).
3.2 Medical Costs
Trends. Medical costs per patient year increased by an average of 3% per year from V3490 to V4536
(std: V4457). The annual percentage increase appeared to be lower in patients with severe lesions (1.2% per
year; Appendix). Hospitalization, outpatient and pharmaceutical costs accounted for ± 45%, 38%, and 18%
of the total cost (Fig. 2). Hospitalization costs increased faster than outpatient costs (3.2% vs. 2.5% per
year; Appendix).
Determinants. Higher total medical costs were found in older age categories, patients with severe
lesions, and women (Tab. 1).
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4.3 Societal Costs
Trends. (Fig. 3) shows a 2.0 percent point (p.p.) increase to 7.4% (std: 7.2%) for invalidity while
incapacity to work decreased 0.4 p.p. to 7.9% (std: 7.8%). Absenteeism-related costs per patient year
increased from V6321 to V8396 (std: V8135). The increase was most pronounced in age categories
≥30 yrs and in patients with mild lesions.
Figure 1: Demographics, stratified for age and lesion complexity, for the first and last year of the
study period
Figure 2: Medical costs per patient year, stratified for pharmaceutical, outpatient and hospitalization costs.
Repartition between out-of-pocket and reimbursed costs
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The proportion of patients unemployed for at least one day in a year decreased 3.1 p.p. to 13.8% (std:
13.8%). Unemployment-related costs per patient year decreased from V7420 to V5373 (std: V5406). The
decrease was most pronounced in patients with severe lesions and in age category ≥40 yrs (Appendix).
Determinants. Higher absenteeism-related costs were found in older age categories, patients with
severe lesions, and women. However, no covariates had a significant impact on unemployment-related
costs (Tab. 1).
4.4 Outpatient Cardiology Visits
Trends. Forty-seven percent of patients visited a cardiologist in 2015, an 11.6 p.p. increase compared to
2006. In particular, there were increases in the proportion of patients with at least one visit to ACHD
specialists (8.7 p.p. to 21%) and to general cardiologists (6.6 p.p. to 35%) (Fig. 4). In 2015, 81%
(+10.9 p.p.) of patients with severe lesions had at least one cardiology visit, and 52% (+12.7 p.p.) had at
least one ACHD specialist visit (Fig. 5). This all corresponded to an increase in total cardiology visits per
patient year from 0.71 to 1.03 (std: 0.98). General cardiology visits were most common, with an increase
from 0.50 to 0.70 (std: 0.67) visits per patient year. Likewise, ACHD specialist visits increased from
Table 1: Generalized Linear Mixed Model with annual outpatient cardiology visits, hospitalization, medical
cost, medical absenteeism-related cost, and unemployment-related cost as dependent variables
Medical costs Medical absenteeism-related costs Unemployment-related costs
Est. p-value % increase Lower Upper Est. p-value % increase Lower Upper Est. p-value % increase Lower Upper
Intercept 7.73 <0.0001 −1.66 <0.0001 −0.46 <0.0001
Age 18–29
Age 30–39 0.23 <0.0001 25% 16% 35% 0.65 <0.0001 91% 78% 104% −0.04 0.29 −4% −10% 3%
Age ≥40 0.61 <0.0001 85% 67% 104% 1.10 <0.0001 202% 174% 233% 0.07 0.11 8% −2% 18%
Mild
Moderate 0.04 0.52 4% −7% 16% 0.00 0.97 0% −12% 14% −0.09 0.10 −9% −18% 2%
Severe 0.45 <0.0001 57% 28% 92% 0.25 0.03 29% 3% 61% −0.09 0.35 −9% −25% 11%
Male
Female 0.11 0.04 12% 1% 24% 0.27 <0.0001 31% 16% 47% −0.09 0.09 −9% −17% 1%
Year 0.04 <0.0001 4% 3% 4% 0.06 <0.0001 6% 6% 7% 0.00 0.54 0% 0% 1%
ACHD specialist General cardiologist Hospitalization
Effect Est. p-value % increase Lower Upper Est. p-value % increase Lower Upper Est. p-value % increase Lower Upper
Intercept −2.43 <0.0001 −1.47 <0.0001 −1.96 <0.0001
Age 18–29
Age 30–39 0.10 0.01 11% 2% 20% 0.37 <0.0001 45% 36% 55% 0.27 <0.0001 31% 23% 40%
Age ≥40 −0.02 0.63 −2% −11% 7% 0.96 <0.0001 160% 143% 179% 0.63 <0.0001 87% 75% 100%
Mild
Moderate 0.95 <0.0001 158% 133% 186% 0.45 <0.0001 57% 46% 68% 0.05 0.18 5% −2% 12%
Severe 1.69 <0.0001 441% 377% 514% 0.94 <0.0001 157% 127% 190% 0.54 <0.0001 72% 54% 93%
Men
Women −0.01 0.84 −1% −9% 8% −0.02 0.48 −2% −8% 5% 0.20 <0.0001 22% 14% 30%
Year 0.06 <0.0001 6% 5% 7% 0.03 <0.0001 3% 3% 4% 0.02 <0.0001 1.7% 1.1% 2.3%
Notes: Confidence Interval = 95%. Intercept ACHD specialist: e−2.43 = 0.088 (0.079–0.099); Intercept general cardiologist: e−1.47 = 0.229 (0.212–
0.248); Intercept hospitalization: e−1.96 = 0.141 (0.130–0.153). Intercept medical cost: e7.73 =V2267 (V2039–V2515); Intercept medical absenteeism-
related cost: e−1.66*10,000=V1893 (V1685–V2126); Intercept unemployment-related cost: e−0.46*10,000 =V6332 (V5716–V7015). Est. = Estimate.
Example: A male patient, 18–29 years old with a mild lesion, in 2006, had an average medical cost of V2267. A male patient, 30–39 years old with a
severe lesion, in 2007 had an average medical cost of V2267*1.25*1.57*1.04 = V4627.
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0.18 to 0.29 (std: 0.27) visits per patient year. The relative increase was strongest in the ≥40 yrs age group and
in patients with moderate lesions (Appendix).
Determinants. The ACHD specialist was visited significantly more by patients aged 30–39, and the
general cardiologist by those aged ≥40 yrs. Higher lesion complexity was related to significantly more
visits to all three cardiologist types. Sex did not have an impact (Tab. 1).
4.5 Other Outpatient HCU
Trends. The annual percentage of patients with at least one outpatient visit to a particular health
professional increased over time, except for visits to other MD specialists (Fig. 4). This corresponded to
increases of 101.7%, 49.6%, 15.2%, 7.1%, and 39.7%, respectively in nursing care visits, physiotherapist
care visits, dental care visits, gynaecology visits, and ED visits per patient year (Appendix).
Determinants. The effect of age and lesion complexity varied by type of HCU, but overall, women
appeared to incur significantly more HCU (Appendix).
4.6 Hospitalization
Trends. The annual hospitalization rate remained stable over time with 16%–17% of patients being
hospitalized (Fig. 4). The number of hospitalizations per patient year however increased from 0.24 to
0.27 (std: 0.26), and the average LOS per hospitalization increased from 9.57 to 10.20 days (std: 10.18).
Importantly, such an increase was only noted in patients with mild or moderate lesions: Decreases in
hospitalization rate from 0.37 to 0.31 and in LOS from 7.8 to 7.4 days were found in patients with severe
lesions (Appendix).
Figure 3: Bars: Real world societal costs related to absenteeism (invalidity + incapacitation) and
unemployment. Lines: Proportion of patients being unemployed, incapacitated, or invalid for at least one
day during a year
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Figure 4: Real world proportion of patients per healthcare utilization type with at least one encounter. 2006
vs. 2015. ACHD: Adult congenital heart disease; MD: medical doctor. Please note that stratified results to
lesion complexity, age, or sex can be found in the appendix online. Stratified results to lesion complexity
for outpatient cardiology visits could be found in (Fig. 5)
Figure 5: Real world proportion of patients with at least one encounter to a general cardiologist or an ACHD
specialist. 2006 to 2015, per year, stratified for lesion complexity
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Determinants. The hospitalization rate was 72% (54%–93%) higher in patients with severe lesions than
in patients with mild lesions. LOS did not differ significantly for lesion complexity. Age categories 30–39
and ≥40 yrs were associated with respectively 31% (23–40%) and 87% (75–100%) more hospitalizations.
Women were 22% (14–30%) more hospitalized than men with a 14% (3–24%) shorter LOS (Tab. 1).
5 Discussion
This longitudinal, multicenter cost-of-illness study made use of a retrospective database linking
administrative and clinical data. This study showed substantial increases in per patient year medical and
absenteeism-related costs, as well as a decrease in unemployment-related costs. The standardized values,
adjusting for the ageing and more complex patient population, mitigated the increase in medical and
absenteeism-related costs to a limited extent. In other words, there would have been a slightly smaller
cost increase if the patient population composition had remained stable over time.
Medical costs. The percentage increase in medical costs over time is higher in patients with mild or
moderate lesions than in patients with severe lesions. Possible explanations for this include the greater
age of the group with mild to moderate lesions, leading to a more rapid increase in comorbidities, a
suboptimal fit between care needs and care received, technological evolution [3], or simply because
patients with severe lesions already incurred high costs before and had an increased mortality rate. A
previous study on medical costs in Belgium was conducted in 1997 [18]. Adjusting for inflation and
excluding pharmaceutical costs (as not all pharmaceutical costs were available), medical costs did not
increase between 1997 and 2006 while our results showed a 29% increase between 2006 and 2015. This
older study was correctly framed as a pilot study because, apparently, an excessively high cost estimate
resulted from selection bias as only patients seen by an ACHD specialist were selected. For example, the
hospitalization rate in that study was substantially higher [18]. Despite the limitations to this comparison,
it seems that costs have recently accelerated, driven by strong increases in outpatient HCU, while the
hospitalization rate per patient year has increased more slowly. However, this acceleration was also
encouraged by the increasing cost per hospitalization which could be explained by the longer LOS [19],
and the greater disease burden, related to the ageing patient population over time [19,20].
Societal costs. Only one previous (US) study calculated the productivity loss cost following
hospitalization [9]. In our study, we calculated the productivity loss cost, taking into account absenteeism
and unemployment. The societal costs of adults with CHD appeared to be higher than their medical costs.
Note that only part of these costs could be attributed specifically to the ACHD pathology as absenteeism
and unemployment are prevalent in the general population as well. Unemployment and invalidity were
the most important cost components of societal costs, with an increasing role being placed by invalidity-
related costs. Invalidity appeared to become more prevalent over time, similarly to trends observed in the
general population [21]. General explanations include medical progress leading to better survival,
increasing labor market participation, and policy measures such as a higher retirement age [22]. Invalidity
in the ACHD population was higher than in the general population (7.4% vs. 5%) despite the fact that
invalidity normally occurs more often after the age of 50 [21], while our ACHD cohort was relatively
young. Unemployment (and its related costs) decreased, while in the general population it remained
stable between 2006 and 2015 and only decreased after 2015 [23], offering positive prospects. Recent
research has demonstrated lower unemployment and invalidity rates in Belgium than in other countries
[8]. Hence, even more pressing societal costs may be encountered elsewhere.
Outpatient cardiology visits. Fewer outpatient cardiology visits were counted among patients with mild
lesions than in previous European studies, while comparable rates were found for patients with moderate and
severe lesions [20,24]. One in five patients with severe lesions had no cardiac follow-up in the last year of the
study period, but increasing numbers of patients received specialized care while hospitalization rates
decreased. Furthermore, general cardiology visits remained more prevalent in patients with mild and
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moderate lesions and in patients ≥40 yrs. In light of the results of Mylotte et al. [25] and Cordina et al. [26],
who demonstrated clinical benefits following ACHD specialist visits, special attention should be given to
guiding patients towards specialist care. However, more research is needed to settle the debate about
shared care for patients with mild and moderate lesions.
In order to correctly interpret the trends in outpatient cardiology visits (cfr. Figs. 4 and 5), it is important
to know that the Belgian ACHD medical care system has undergone continuous development in recent
decades. The Belgian healthcare system is characterized by a high degree of accessibility and freedom of
choice. Most ACHD patients were diagnosed in childhood, during which time they are followed by
pediatric cardiologists. During adolescence, the pediatric cardiologist makes the call to start the transition
process to adult services. For example, the transition program of Ghent University Hospital, which has
been described in detail by de Hosson et al. [27] developed gradually during the study period, before
becoming fully operational in 2015. The development of such transition programs has taken many years,
and is a major aspect of the continuously improving ACHD medical care system. Better transition to
adult services is surely one of the reasons that an increasing proportion of ACHD patients are receiving
regular follow-up by ACHD specialists. All ACHD patients are encouraged to remain under periodic
specialized follow-up as the long-term consequences are yet to be scrutinized. A decision can be made in
consultation between the patient and the ACHD specialist to have periodic follow-up elsewhere as well.
In this regard, Goossens et al. [28] demonstrated a low lost-to-follow-up rate after transition in Belgium.
As mentioned before, patients also have the freedom to remain under the follow-up of a pediatric
cardiologist, although this is generally exceptional, all the more since admission to pediatric services is
not allowed above age 15.
Other. Other outpatient HCU in this study is higher than in the Dutch study of Schoormans et al. [7]
(e.g., >80% vs. 40% of patients visiting a GP in the course of a year). Apart from healthcare system
differences, dissimilarities in research aims may explain these differences. Schoormans et al. [7] assessed
cardiac disease-related outpatient visits only, whereas we assessed outpatient visits regardless of cause.
Our longitudinal analysis revealed increases in most types of HCU which were more pronounced in
patients with mild and moderate lesions. This is in line with the results obtained for outpatient cardiology
visits (in this and in previous research [25]): Patients with mild and moderate lesions are older, leading to
a more pronounced increase in HCU. One important type of HCU is dental care to prevent infective
endocarditis [29]. Annual visits are highly recommended for many patients with ACHD. An increase in
dental care has been noted over the study period, resulting in 67% of the patients receiving dental care in
2015. This is substantially lower than found in a recent self-reporting study (86% in Belgium) [30],
suggesting a self-reporting bias, and warranting continued patient education. Dental care in adults with
CHD is, however, better than dental care in the general population (±50%) [31].
Sex. Previous literature on sex disparities was inconclusive even though there seemed to be a tendency
towards more HCU in women [3]. This study supported the thesis of higher medical costs in women although
the cost per hospitalization was higher in men. Several explanations can be put forward to explain this
disparity such as the impact of pregnancy management and –related hospitalization [32]. Previous
research also suggested that, overall, women experience fewer barriers to making use of available
healthcare services subsequently leading to a lower need for long-term inpatient care [33].
5.1 Strengths and Limitations
A particular strength of this study is that the cost estimations are sound and robust as our approach meets
the most important recommendations on how to conduct a cost-of-illness study: Our calculation stems from a
database linking clinical, demographic, resource use, and actual cost data [34–36], taking into account a
broad range of cost components [13]. A number of limitations should be addressed as well. First, the
retrospective data were not primarily gathered to answer specific research questions [37]. For example,
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we were not able to specifically determine details of hospitalizations such as the medical department in which
they took place. Administrative databases are also prone to miscoding and missing data [37]. However,
retrospective database research is a low-cost solution to providing a large sample size, which counters the
small number of miscoded and missing data [37]. Second, the BELCODAC is built on all ACHD patients
affiliated with the two Flemish tertiary centers. Only patients with severe lesions were included from the
third center. However, the oversampling of patients with severe lesions does not impede generalization
because the patients included from the third hospital accounted for less than 2% of included patients.
Third, although our study sample is comparable to those in other countries [11], an initial selection bias
towards more severe lesions cannot be excluded as only patients who were ever seen in an academic
hospital were included. Patients with less severe lesions who never need to be referred to an academic
hospital were thus missed [11]. Fourth, we did not analyze HCU for specific congenital anomalies
separately. For example, we did not analyze different mild lesions separately despite possible differences
in HCU [3]. Fifth, our calculation did not include HCU that cannot be reimbursed. For example, adult
psychotherapy is only reimbursed in some rare cases, and is therefore only partly included in our
analyses. Sixth, how societal costs should be calculated has been a point of discussion for many years.
Every estimation is a function of some assumptions. In our calculations, for example, as suggested by
Hankivsky et al. [38], we made use of the average population earnings in order to not discriminate by
sex, age or profession.
6 Conclusion
Despite some limitations, this study has important added value because, to date, no comprehensive
cost-of-illness research had been conducted in the ACHD population. The importance and applicability
of cost-of-illness studies for clinicians and policy makers is manifold as it can help determine the most
appropriate care level, populate cost-effectiveness models, and provide insight into future budget
impact. This study demonstrated increased access to specialized cardiac care, lower unemployment, and
more long-term invalidity. Overall, the medical cost increase is most pronounced for patients with mild
or moderate lesions, probably due to their higher age. The analysis of past data adds to our
understanding of the future financial burden of ACHD care with unchanged policies. It is a collective
responsibility to provide our patients with appropriate care while making efforts to limit the financial
burden on both patients and society.
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Appendix
Proportion of Patients Making Use of a Certain Type of Healthcare Utilization
ACHD specialist
Pediatric cardiologist
2006 2015 p.p. change p.p. change per year
REALWORLD Total 12.6% 21.3% 8.7% 1.0%
Female 11.4% 19.2% 7.8% 0.9%
Male 13.9% 23.5% 9.6% 1.1%
18–29 17.0% 23.4% 6.4% 0.7%
30–39 14.1% 24.3% 10.2% 1.1%
40+ 6.8% 17.3% 10.5% 1.2%
Mild 5.7% 10.8% 5.1% 0.6%
Moderate 17.5% 28.0% 10.5% 1.2%
Severe 38.9% 51.6% 12.7% 1.4%
STANDARDIZED Total 12.6% 20.4% 7.8% 0.9%
2006 2015 p.p. change p.p. change per year
REALWORLD Total 2.2% 3.3% 1.1% 0.1%
Female 2.0% 2.9% 0.9% 0.1%
Male 2.4% 3.7% 1.3% 0.1%
18–29 3.6% 6.1% 2.5% 0.3%
30–39 1.2% 1.9% 0.7% 0.1%
40+ 1.1% 1.3% 0.1% 0.0%
Mild 0.8% 1.0% 0.2% 0.0%
Moderate 2.4% 3.8% 1.4% 0.2%
Severe 12.3% 14.5% 2.2% 0.2%
STANDARDIZED Total 2.2% 3.1% 0.9% 0.1%




2006 2015 p.p. change p.p. change per year
REALWORLD Total 27.9% 34.5% 6.6% 0.7%
Female 26.7% 32.4% 5.7% 0.6%
Male 29.2% 36.7% 7.5% 0.8%
18–29 23.3% 27.1% 3.8% 0.4%
30–39 25.7% 30.9% 5.2% 0.6%
40+ 34.2% 44.0% 9.7% 1.1%
Mild 22.4% 28.4% 6.0% 0.7%
Moderate 32.3% 39.0% 6.7% 0.7%
Severe 45.1% 49.0% 4.0% 0.4%
STANDARDIZED Total 27.9% 33.5% 5.6% 0.6%
2006 2015 p.p. change p.p. change per year
AL WORLD Total 35.4% 47.0% 11.6% 1.3%
Female 33.2% 44.1% 10.9% 1.2%
Male 37.8% 50.2% 12.4% 1.4%
18–29 35.4% 43.1% 7.7% 0.9%
30–39 32.8% 43.9% 11.2% 1.2%
40+ 37.0% 52.8% 15.8% 1.8%
Mild 25.8% 34.6% 8.7% 1.0%
Moderate 42.6% 55.5% 13.0% 1.4%
Severe 69.9% 80.8% 10.9% 1.2%
STANDARDIZED Total 35.4% 45.6% 10.2% 1.1%
2006 2015 p.p. change p.p. change per year
REALWORLD Total 80.1% 86.1% 6.0% 0.7%
Female 84.6% 90.1% 5.5% 0.6%
Male 75.3% 81.9% 6.6% 0.7%
18–29 78.7% 81.6% 2.9% 0.3%
30–39 78.5% 86.5% 8.0% 0.9%
40+ 82.8% 90.4% 7.6% 0.8%
Mild 80.9% 87.4% 6.5% 0.7%
Moderate 79.6% 85.4% 5.9% 0.7%
Severe 77.6% 81.8% 4.2% 0.5%
STANDARDIZED Total 80.1% 86.1% 5.9% 0.7%




2006 2015 p.p. change p.p. change per year
REALWORLD Total 18.6% 24.8% 6.2% 0.7%
Female 21.4% 29.2% 7.8% 0.9%
Male 15.5% 20.0% 4.5% 0.5%
18–29 15.2% 18.3% 3.1% 0.3%
30–39 19.7% 26.5% 6.8% 0.8%
40+ 21.8% 30.1% 8.4% 0.9%
Mild 19.1% 26.0% 6.9% 0.8%
Moderate 18.1% 24.3% 6.2% 0.7%
Severe 18.2% 19.7% 1.5% 0.2%
STANDARDIZED Total 18.6% 24.6% 6.0% 0.7%
2006 2015 p.p. change p.p. change per year
REALWORLD Total 32.6% 33.9% 1.2% 0.1%
Female 32.6% 33.9% 1.2% 0.1%
Male – – – –
18–29 30.7% 29.3% −1.4% −0.2%
30–39 44.7% 46.4% 1.7% 0.2%
40+ 27.6% 30.7% 3.2% 0.4%
Mild 32.9% 34.8% 1.9% 0.2%
Moderate 32.1% 32.1% 0.0% 0.0%
Severe 34.0% 36.8% 2.8% 0.3%
STANDARDIZED Total 32.6% 33.7% 1.0% 0.1%
2006 2015 p.p. change p.p. change per year
REALWORLD Total 53.8% 66.7% 12.9% 1.4%
Female 57.9% 70.2% 12.3% 1.4%
Male 49.4% 62.9% 13.6% 1.5%
18–29 54.8% 65.0% 10.2% 1.1%
30–39 55.1% 68.4% 13.2% 1.5%
40+ 51.9% 67.4% 15.5% 1.7%
Mild 53.1% 66.2% 13.0% 1.4%
Moderate 54.8% 67.4% 12.6% 1.4%
Severe 53.2% 66.5% 13.3% 1.5%
STANDARDIZED Total 53.8% 66.6% 12.8% 1.4%




2006 2015 p.p. change p.p. change per year
REALWORLD Total 72.8% 70.5% −2.4% −0.3%
Female 78.8% 76.1% −2.8% −0.3%
Male 66.3% 64.5% −1.8% −0.2%
18–29 70.1% 62.3% −7.9% −0.9%
30–39 71.7% 67.9% −3.8% −0.4%
40+ 76.6% 80.2% 3.7% 0.4%
Mild 71.5% 70.9% −0.6% −0.1%
Moderate 73.5% 69.9% −3.5% −0.4%
Severe 80.2% 70.5% −9.7% −1.1%
STANDARDIZED Total 72.8% 70.1% −2.8% −0.3%
2008 2015 p.p. change p.p. change per year
REALWORLD Total 14.0% 17.4% 3.5% 0.4%
Female 13.5% 17.7% 4.2% 0.5%
Male 14.5% 17.2% 2.7% 0.3%
18–29 14.9% 18.0% 3.1% 0.3%
30–39 13.1% 15.8% 2.7% 0.3%
40+ 13.5% 17.8% 4.4% 0.5%
Mild 13.4% 17.0% 3.5% 0.4%
Moderate 13.8% 17.1% 3.3% 0.4%
Severe 19.6% 22.6% 3.0% 0.3%
STANDARDIZED Total 14.0% 17.4% 3.4% 0.4%
2006 2015 p.p. change p.p. change per year
REALWORLD Total 16.1% 16.7% 0.6% 0.1%
Female 18.2% 19.1% 0.9% 0.1%
Male 13.7% 14.1% 0.4% 0.0%
18–29 13.1% 11.7% −1.4% −0.2%
30–39 15.5% 16.7% 1.3% 0.1%
40+ 19.7% 21.7% 2.0% 0.2%
Mild 15.7% 17.0% 1.3% 0.1%
Moderate 15.4% 16.0% 0.6% 0.1%
Severe 23.3% 18.5% −4.8% −0.5%
STANDARDIZED Total 16.1% 16.4% 0.4% 0.0%




2006 2015 p.p. change p.p. change per year
REALWORLD Total 7.4% 10.4% 3.0% 0.3%
Female 9.4% 12.8% 3.4% 0.4%
Male 5.2% 7.8% 2.7% 0.3%
18–29 4.6% 7.6% 3.0% 0.3%
30–39 7.5% 10.8% 3.3% 0.4%
40+ 10.4% 12.9% 2.5% 0.3%
Mild 7.6% 10.8% 3.2% 0.4%
Moderate 7.0% 10.1% 3.1% 0.3%
Severe 7.7% 9.2% 1.5% 0.2%
STANDARDIZED Total 7.4% 10.3% 2.9% 0.3%
2006 2015 p.p. change p.p. change per year
REALWORLD Total 16.9% 13.8% −3.1% −0.3%
Female 15.9% 11.4% −4.5% −0.5%
Male 16.4% −1.6% −0.2%
18–29 18.6% 14.3% −4.3% −0.5%
30–39 16.4% 15.0% −1.4% −0.2%
40+ 14.9% 12.2% −2.7% −0.3%
Mild 17.0% 13.4% −3.6% −0.4%
Moderate 16.6% 14.2% −2.4% −0.3%
Severe 17.3% 13.9% −3.4% −0.4%
STANDARDIZED Total 16.9% 13.8% −3.0% −0.3%
2006 2015 p.p. change p.p. change per year
REALWORLD Total 12.9% 14.4% 1.5% 0.2%
Female 13.3% 15.8% 2.5% 0.3%
Male 12.5% 12.9% 0.3% 0.0%
18–29 7.9% 6.1% −1.8% −0.2%
30–39 13.8% 15.2% 1.4% 0.2%
40+ 18.8% 23.9% 5.1% 0.6%
Mild 12.8% 14.5% 1.7% 0.2%
Moderate 12.6% 14.3% 1.7% 0.2%
Severe 15.7% 13.8% −1.9% −0.2%
STANDARDIZED Total 12.9% 14.1% 1.2% 0.1%
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Incapacitated for work
Invalidity
Frequency of healthcare utilization per patient year
ACHD specialist
2006 2015 p.p. change p.p. change per year
REALWORLD Total 8.2% 7.9% −0.4% 0.0%
Female 7.8% 8.3% 0.5% 0.1%
Male 8.7% 7.5% −1.2% −0.1%
18–29 7.2% 5.3% −1.8% −0.2%
30–39 9.3% 9.6% 0.3% 0.0%
40+ 8.9% 9.7% 0.8% 0.1%
Mild 8.6% 7.9% −0.7% −0.1%
Moderate 7.8% 8.0% 0.2% 0.0%
Severe 8.0% 6.6% −1.3% −0.1%
STANDARDIZED Total 8.2% 7.8% −0.4% 0.0%
2006 2015 p.p. change p.p. change per year
REALWORLD Total 5.4% 7.4% 2.0% 0.2%
Female 6.2% 8.7% 2.6% 0.3%
Male 4.7% 6.1% 1.4% 0.2%
18–29 1.0% 1.2% 0.2% 0.0%
30–39 5.2% 6.6% 1.4% 0.2%
40+ 11.4% 15.6% 4.3% 0.5%
Mild 5.1% 7.7% 2.6% 0.3%
Moderate 5.5% 6.9% 1.5% 0.2%
Severe 8.0% 8.4% 0.4% 0.0%
STANDARDIZED Total 5.4% 7.2% 1.7% 0.2%
2006 2015 % change % yearly change
REALWORLD Total 0.18 0.29 58.2% 5.2%
Female 0.16 0.27 66.6% 5.8%
Male 0.20 0.30 50.4% 4.6%
18–29 0.21 0.29 37.8% 3.6%
30–39 0.24 0.35 46.0% 4.3%
40+ 0.11 0.25 117.4% 9.0%
Mild 0.10 0.14 38.1% 3.7%
Moderate 0.22 0.38 69.9% 6.1%
Severe 0.61 0.74 21.7% 2.2%
STANDARDIZED Total 0.18 0.27 50.3% 4.6%




2006 2015 % change % yearly change
REALWORLD Total 0.03 0.04 51.9% 4.8%
Female 0.03 0.04 38.6% 3.7%
Male 0.03 0.05 63.5% 5.6%
18–29 0.05 0.08 65.6% 5.8%
30–39 0.02 0.03 49.3% 4.6%
40+ 0.01 0.02 29.4% 2.9%
Mild 0.01 0.01 37.0% 3.6%
Moderate 0.03 0.04 66.5% 5.8%
Severe 0.20 0.22 10.5% 1.1%
STANDARDIZED Total 0.03 0.04 41.2% 3.9%
2006 2015 % change % yearly change
REALWORLD Total 0.50 0.70 40.5% 3.9%
Female 0.51 0.67 31.8% 3.1%
Male 0.49 0.74 50.2% 4.6%
18–29 0.34 0.41 19.7% 2.0%
30–39 0.45 0.52 14.1% 1.5%
40+ 0.70 1.11 57.1% 5.1%
Mild 0.42 0.56 32.8% 3.2%
Moderate 0.55 0.81 47.0% 4.4%
Severe 0.86 1.07 23.4% 2.4%
STANDARDIZED Total 0.50 0.67 33.8% 3.3%
2006 2015 % change % yearly change
REALWORLD Total 0.71 1.03 45.5% 4.3%
Female 0.70 0.98 40.3% 3.8%
Male 0.73 1.09 50.8% 4.7%
18–29 0.60 0.78 29.7% 2.9%
30–39 0.71 0.89 25.6% 2.6%
40+ 0.83 1.37 65.0% 5.7%
Mild 0.53 0.71 33.9% 3.3%
Moderate 0.80 1.23 54.1% 4.9%
Severe 1.68 2.03 21.2% 2.2%
STANDARDIZED Total 0.71 0.98 38.3% 3.7%




2006 2015 % change % yearly change
REALWORLD Total 5.02 5.36 6.6% 0.7%
Female 5.69 6.09 7.2% 0.8%
Male 4.30 4.56 6.3% 0.7%
18–29 3.78 3.84 1.4% 0.2%
30–39 4.49 4.91 9.4% 1.0%
40+ 6.75 7.15 6.0% 0.6%
Mild 5.12 5.53 8.1% 0.9%
Moderate 4.87 5.23 7.2% 0.8%
Severe 5.24 4.95 −5.5% −0.6%
STANDARDIZED Total 5.02 5.29 5.2% 0.6%
2006 2015 % change % yearly change
REALWORLD Total 3.73 5.58 49.6% 4.6%
Female 4.12 6.53 58.4% 5.2%
Male 3.30 4.56 38.1% 3.7%
18–29 3.09 4.07 31.6% 3.1%
30–39 3.61 5.43 50.3% 4.6%
40+ 4.53 7.19 58.9% 5.3%
Mild 3.36 5.65 68.1% 5.9%
Moderate 3.92 5.34 36.3% 3.5%
Severe 5.67 6.41 13.0% 1.4%
STANDARDIZED Total 3.73 5.49 47.0% 4.4%
2006 2015 % change % yearly change
REALWORLD Total 0.98 1.05 7.1% 0.8%
Female 0.98 1.05 7.1% 0.8%
Male – – – –
18–29 1.08 1.11 3.2% 0.3%
30–39 1.73 1.87 8.1% 0.9%
40+ 0.43 0.51 16.7% 1.7%
Mild 0.92 1.07 15.6% 1.6%
Moderate 1.08 0.99 −8.7% −1.0%
Severe 0.91 1.33 46.2% 4.3%
STANDARDIZED Total 0.98 1.05 7.3% 0.8%




2006 2015 % change % yearly change
REALWORLD Total 1.21 1.39 15.2% 1.6%
Female 1.30 1.45 12.1% 1.3%
Male 1.11 1.32 19.3% 2.0%
18–29 1.22 1.33 8.7% 0.9%
30–39 1.25 1.40 11.8% 1.2%
40+ 1.16 1.45 24.4% 2.5%
Mild 1.20 1.39 15.5% 1.6%
Moderate 1.22 1.39 13.6% 1.4%
Severe 1.17 1.42 22.0% 2.2%
STANDARDIZED Total 1.21 1.39 14.9% 1.6%
2006 2015 % change % yearly change
REALWORLD Total 2.97 3.09 3.8% 0.4%
Female 3.49 3.62 3.7% 0.4%
Male 2.41 2.52 4.5% 0.5%
18–29 2.28 2.12 −6.9% −0.8%
30–39 2.90 2.70 −6.7% −0.8%
40+ 3.80 4.29 12.8% 1.3%
Mild 3.00 3.31 10.3% 1.1%
Moderate 2.89 2.90 0.4% 0.0%
Severe 3.28 2.65 −19.3% −2.4%
STANDARDIZED Total 2.97 3.05 2.6% 0.3%
2008 2015 % change % yearly change
REALWORLD Total 0.18 0.26 39.7% 4.9%
Female 0.18 0.27 50.7% 6.0%
Male 0.19 0.24 28.4% 3.6%
18–29 0.19 0.27 39.2% 4.8%
30–39 0.17 0.24 44.1% 5.4%
40+ 0.18 0.26 38.1% 4.7%
Mild 0.17 0.24 41.2% 5.1%
Moderate 0.18 0.25 41.3% 5.1%
Severe 0.30 0.36 18.3% 2.4%
STANDARDIZED Total 0.18 0.25 39.1% 4.8%




2006 2015 % change % yearly change
REALWORLD Total 0.24 0.27 11.7% 1.2%
Female 0.26 0.31 19.4% 2.0%
Male 0.22 0.22 2.0% 0.2%
18–29 0.19 0.18 −6.7% −0.8%
30–39 0.22 0.25 16.8% 1.7%
40+ 0.30 0.36 18.9% 1.9%
Mild 0.23 0.26 14.3% 1.5%
Moderate 0.23 0.26 13.2% 1.4%
Severe 0.37 0.31 −13.9% −1.6%
STANDARDIZED Total 0.24 0.26 9.1% 1.0%
2007 2015 % change % yearly change
REALWORLD Total 9.57 10.20 6.6% 0.8%
Female 9.46 9.17 −3.1% −0.4%
Male 9.72 11.73 20.7% 2.4%
18–29 10.58 12.40 17.3% 2.0%
30–39 7.35 10.47 42.5% 4.5%
40+ 9.94 8.99 −9.6% −1.3%
Mild 9.87 10.76 9.0% 1.1%
Moderate 9.61 10.18 5.8% 0.7%
Severe 7.77 7.36 −5.2% −0.7%
STANDARDIZED Total 9.57 10.18 6.4% 0.8%
2006 2015 % change % yearly change
REALWORLD Total 3.57 7.20 101.5% 8.1%
Female 3.87 7.52 94.3% 7.7%
Male 3.24 6.86 111.3% 8.7%
18–29 1.94 4.22 117.6% 9.0%
30–39 2.32 4.70 102.7% 8.2%
40+ 6.18 11.71 89.4% 7.4%
Mild 3.54 7.46 110.7% 8.6%
Moderate 3.45 7.08 105.5% 8.3%
Severe 4.70 6.20 32.0% 3.1%
STANDARDIZED Total 3.57 7.03 96.7% 7.8%
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2006 2015 % change % yearly change
REALWORLD Total 3 490 V 4 536 V 30.0% 3.0%
Female 3 549 V 4 778 V 34.6% 3.4%
Male 3 425 V 4 276 V 24.9% 2.5%
18–29 2 515 V 3 395 V 35.0% 3.4%
30–39 2 951 V 3 716 V 25.9% 2.6%
40+ 4 916 V 6 178 V 25.7% 2.6%
Mild 3 559 V 4 521 V 27.0% 2.7%
Moderate 3 256 V 4 477 V 37.5% 3.6%
Severe 4 455 V 4 942 V 10.9% 1.2%
STANDARDIZED Total 3 490 V 4 457 V 27.7% 2.8%
2006 2015 % change % yearly change
REALWORLD Total 1 534 V 2 037 V 32.8% 3.2%
Female 1 526 V 2 094 V 37.2% 3.6%
Male 1 543 V 1 977 V 28.1% 2.8%
18–29 1 144 V 1 416 V 23.8% 2.4%
30–39 1 371 V 1 690 V 23.3% 2.4%
40+ 2 073 V 2 871 V 38.5% 3.7%
Mild 1 496 V 1 992 V 33.1% 3.2%
Moderate 1 502 V 2 017 V 34.3% 3.3%
Severe 2 072 V 2 427 V 17.1% 1.8%
STANDARDIZED Total 1 534 V 1 983 V 29.3% 2.9%
2006 2015 % change % yearly change
REALWORLD Total 6 447 V 7 669 V 19.0% 1.9%
Female 5 940 V 6 826 V 14.9% 1.6%
Male 7 108 V 8 925 V 25.6% 2.6%
18–29 5 988 V 7 939 V 32.6% 3.2%
30–39 6 357 V 6 711 V 5.6% 0.6%
40+ 6 810 V 7 939 V 16.6% 1.7%
Mild 6 527 V 7 601 V 16.5% 1.7%
Moderate 6 528 V 7 740 V 18.6% 1.9%
Severe 5 669 V 7 712 V 36.0% 3.5%
STANDARDIZED Total 6 447 V 7 797 V 20.9% 2.1%




2006 2015 % change % yearly change
REALWORLD Total 1 331 V 1 669 V 25.4% 2.5%
Female 1 306 V 1 831 V 40.2% 3.8%
Male 1 360 V 1 495 V 10.0% 1.1%
18–29 981 V 1 260 V 28.5% 2.8%
30–39 1 044 V 1 400 V 34.1% 3.3%
40+ 1 902 V 2 243 V 17.9% 1.8%
Mild 1 421 V 1 686 V 18.6% 1.9%
Moderate 1 203 V 1 638 V 36.1% 3.5%
Severe 1 416 V 1 728 V 22.0% 2.2%
STANDARDIZED Total 1 331 V 1 643 V 23.4% 2.4%
2006 2015 % change % yearly change
REALWORLD Total 624 V 830 V 32.9% 3.2%
Female 717 V 854 V 19.1% 2.0%
Male 522 V 804 V 53.9% 4.9%
18–29 390 V 719 V 84.1% 7.0%
30–39 537 V 627 V 16.8% 1.7%
40+ 941 V 1 064 V 13.1% 1.4%
Mild 642 V 843 V 31.4% 3.1%
Moderate 551 V 822 V 49.1% 4.5%
Severe 967 V 787 V −18.6% −2.3%
STANDARDIZED Total 624 V 830 V 32.9% 3.2%
2006 2015 % change % yearly change
REALWORLD Total 7 420 V 5 373 V −27.6% −3.5%
Female 7 991 V 4 946 V −38.1% −5.2%
Male 6 801 V 5 824 V −14.4% −1.7%
18–29 6 493 V 4 950 V −23.8% −3.0%
30–39 6 844 V 5 559 V −18.8% −2.3%
40+ 9 030 V 5 753 V −36.3% −4.9%
Mild 7 757 V 5 667 V −26.9% −3.4%
Moderate 6 939 V 5 133 V −26.0% −3.3%
Severe 7 826 V 4 899 V −37.4% −5.1%
STANDARDIZED Total 7 420 V 5 406 V −27.1% −3.5%
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Societal cost: medical absenteeism
Generalized Linear Mixed Models
Total medical cost
Societal cost: unemployment
2006 2015 % change % yearly change
REALWORLD Total 6 321 V 8 396 V 32.8% 3.2%
Female 7 057 V 9 700 V 37.5% 3.6%
Male 5 523 V 7 018 V 27.1% 2.7%
18–29 1 814 V 1 922 V 6.0% 0.6%
30–39 6 213 V 7 913 V 27.4% 2.7%
40+ 12 239 V 16 682 V 36.3% 3.5%
Mild 6 032 V 8 645 V 43.3% 4.1%
Moderate 6 429 V 7 990 V 24.3% 2.4%
Severe 7 953 V 9 016 V 13.4% 1.4%
STANDARDIZED Total 6 321 V 8 135 V 28.7% 2.8%
Estimate p-value % increase Lower Upper
Intercept 7.73 <0.0001
Age 18–29
Age 30–39 0.23 <0.0001 25% 16% 35%
Age 40+ 0.61 <0.0001 85% 67% 104%
Mild
Moderate 0.04 0.515 4% −7% 16%
Severe 0.45 <0.0001 57% 28% 92%
Male
Female 0.11 0.035 12% 1% 24%
Year 0.04 <0.0001 4% 3% 4%
Effect Estimate p-value % increase Lower Upper
Intercept −0.46 <0.0001
Age 18–29
Age 30–39 −0.04 0.2866 −4% −10% 3%
Age 40+ 0.07 0.1119 8% −2% 18%
Mild
Moderate −0.09 0.1041 −9% −18% 2%
Severe −0.09 0.3524 −9% −25% 11%
Men
Women −0.09 0.0861 −9% −17% 1%
Year 0.00 0.5412 0% 0% 1%
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Effect Estimate p-value % increase Lower Upper
Intercept −1.66 <0.0001
Age 18–29
Age 30–39 0.65 <0.0001 90.9% 78.2% 104.5%
Age 40+ 1.10 <0.0001 201.8% 173.8% 232.7%
Mild
Moderate 0.00 0.9737 0.2% −11.6% 13.5%
Severe 0.25 0.0288 28.6% 2.6% 61.2%
Men
Women 0.27 <0.0001 31.4% 16.7% 48.1%
Year 0.06 <0.0001 6.5% 5.8% 7.2%
Effect Estimate p-value % increase Lower Upper
Intercept −2.43 <0.0001
Age 18–29
Age 30–39 0.10 0.0122 11% 2% 20%
Age 40+ −0.02 0.6266 −2% −11% 7%
Mild
Moderate 0.95 <0.0001 158% 133% 186%
Severe 1.69 <0.0001 441% 377% 514%
Men
Women −0.01 0.8379 −1% −9% 8%
Year 0.06 <0.0001 6% 5% 7%
Effect Estimate p-value % increase Lower Upper
Intercept −3.94 <0.0001
Age 18–29
Age 30–39 −0.57 <0.0001 −43% −50% −36%
Age 40+ −0.95 <0.0001 −61% −68% −54%
Mild
Moderate 1.07 <0.0001 192% 137% 259%
Severe 2.63 <0.0001 1288% 1015% 1627%
Men
Women 0.01 0.9438 1% −13% 17%
Year 0.01 0.0797 1% 0% 2%




Effect Estimate p-value % increase Lower Upper
Intercept −1.47 <0.0001
Age 18–29
Age 30–39 0.37 <0.0001 45% 36% 55%
Age 40+ 0.96 <0.0001 160% 143% 179%
Mild
Moderate 0.45 <0.0001 57% 46% 68%
Severe 0.94 <0.0001 157% 127% 190%
Men
Women −0.02 0.4817 −2% −8% 5%
Year 0.03 <0.0001 3% 3% 4%
Effect Estimate p-value % increase Lower Upper
Intercept −1.02 <0.0001
Age 18–29
Age 30–39 0.23 <0.0001 26% 19% 33%
Age 40+ 0.61 <0.0001 84% 73% 94%
Mild
Moderate 0.58 <0.0001 78% 68% 89%
Severe 1.26 <0.0001 254% 223% 289%
Men
Women −0.02 0.4817 −2% −7% 4%
Year 0.04 <0.0001 4% 4% 5%
Effect Estimate p-value % increase Lower Upper
Intercept 1.25 <0.0001
Age 18–29
Age 30–39 0.14 <0.0001 15% 13% 17%
Age 40+ 0.33 <0.0001 39% 35% 44%
Mild
Moderate −0.01 0.78 −1% −4% 3%
Severe 0.04 0.26 4% −3% 12%
Male
Female 0.28 <0.0001 33% 28% 38%
Year 0.01 <0.0001 1% 1% 1%




Effect Estimate p-value % increase Lower Upper
Intercept 0.98 <0.0001
Age 18–29
Age 30–39 0.12 0.00 12% 5% 20%
Age 40+ 0.26 <0.0001 30% 18% 42%
Mild
Moderate −0.05 0.45 −5% −15% 8%
Severe 0.20 0.06 22% −1% 50%
Male
Female 0.29 <0.0001 34% 19% 50%
Year 0.05 <0.0001 6% 5% 6%
Effect Estimate p-value % increase Lower Upper
Intercept −2.94 0.01
Age 18–29
Age 30–39 0.29 0.09 34% −20% 0%
Age 40+ −0.66 0.04 −48% −71% −8%
Mild
Moderate −0.18 0.16 −17% −54% 49%
Severe −0.32 0.17 −27% −76% 116%
Male
Female
Year 0.02 0.05 2% −3% 8%
Effect Estimate p-value % increase Lower Upper
Intercept 0.15 <0.0001
Age 18–29
Age 30–39 0.01 0.42 1% −2% 4%
Age 40+ 0.02 0.28 2% −1% 5%
Mild
Moderate 0.01 0.46 1% −2% 5%
Severe 0.00 0.88 0% −6% 6%
Male
Female 0.12 <0.0001 12% 9% 16%
Year 0.01 <0.0001 1% 0% 1%




Effect Estimate p-value % increase Lower Upper
Intercept 0.64 <0.0001
Age 18–29
Age 30–39 0.18 <0.0001 20% 16% 23%
Age 40+ 0.46 <0.0001 59% 53% 65%
Mild
Moderate −0.02 0.30 −2% −6% 2%
Severe 0.06 0.15 6% −2% 14%
Male
Female 0.33 <0.0001 39% 34% 44%
Year 0.01 0.00 1% 0% 1%
Effect Estimate p-value % increase Lower Upper
Intercept −1.78 <0.0001
Age 18–29
Age 30–39 −0.04 0.27 −4% −10% 3%
Age 40+ 0.07 0.05 7% 0% 15%
Mild
Moderate 0.01 0.76 1% −6% 8%
Severe 0.45 <0.0001 57% 39% 78%
Male
Female −0.01 0.81 −1% −7% 6%
Year 0.04 <0.0001 4% 4% 5%
Effect Estimate p-value % increase Lower Upper
Intercept −1.96 <0.0001
Age 18–29
Age 30–39 0.27 <0.0001 31% 23% 40%
Age 40+ 0.63 <0.0001 87% 75% 100%
Mild
Moderate 0.05 0.18 5% −2% 12%
Severe 0.54 <0.0001 72% 54% 93%
Male
Female 0.20 <0.0001 22% 14% 30%
Year 0.02 <0.0001 1.7% 1.1% 2.3%
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Length of stay
Nursing care
Effect Estimate p-value % increase Lower Upper
Intercept −2.08 <0.0001
Age 18–29
Age 30–39 −0.17 0.02 −16% −27% −3%
Age 40+ 0.10 0.13 11% −3% 27%
Mild
Moderate −0.01 0.82 −1% −13% 12%
Severe −0.11 0.32 −11% −29% 12%
Male
Female −0.15 0.02 −14% −24% −3%
Year 0.03 0.00 3% 1% 4%
Effect Estimate p-value % increase Lower Upper
Intercept −3.80 <0.0001
Age 18–29
Age 30–39 0.15 0.01 16% 3% 30%
Age 40+ 0.52 <0.0001 69% 43% 99%
Mild
Moderate −0.01 0.90 −1% −21% 24%
Severe −0.12 0.57 −11% −41% 34%
Male
Female 0.15 0.18 16% −7% 44%
Year 0.11 <0.0001 12% 11% 13%
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